Opdivo (nivolumab) Plus Yervoy (ipilimumab) Treatments: CheckMate 743 Study [Opdivo plus Yervoy treatments have] demonstrated long-term, durable survival benefit as first-line treatment in patients with various solid tumor types. The randomized phase III CheckMate 743 study demonstrated significant overall survival (OS) benefit with [Opdivo plus … [Read more...]
Nivolumab plus ipilimumab confers sustained OS benefit in malignant pleural mesothelioma
Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line treatment for unresectable malignant pleural mesothelioma, according to randomized phase 3 trial data released by the manufacturer. The open-label, multicenter CheckMate-743 trial included 605 patients who received six cycles of pemetrexed and … [Read more...]